During the last session, Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares were 1.38 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $7.40, reflecting an intraday loss of -4.39% or -$0.34. The 52-week high for the STOK share is $17.58, that puts it down -137.57 from that peak though still a striking 2.43% gain since the share price plummeted to a 52-week low of $7.22. The company’s market capitalization is $400.17M, and the average intraday trading volume over the past 10 days was 1.02 million shares, and the average trade volume was 818.69K shares over the past three months.
Stoke Therapeutics Inc (STOK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. STOK has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Stoke Therapeutics Inc (STOK) registered a -4.39% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.39% in intraday trading to $7.40, hitting a weekly high. The stock’s 5-day price performance is -10.41%, and it has moved by -10.30% in 30 days. Based on these gigs, the overall price performance for the year is 17.46%. The short interest in Stoke Therapeutics Inc (NASDAQ:STOK) is 11.71 million shares and it means that shorts have 15.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies an increase of 58.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $18 respectively. As a result, STOK is trading at a discount of -143.24% off the target high and -143.24% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.74%. While earnings are projected to return 27.50% in 2025, the next five years will return -14.94% per annum.
STOK Dividends
Stoke Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-17. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Stoke Therapeutics Inc insiders own 4.82% of total outstanding shares while institutional holders control 108.25%, with the float percentage being 113.73%. SKORPIOS TRUST is the largest shareholder of the company, while 178.0 institutions own stock in it. As of 2024-06-30, the company held over 10.84 million shares (or 19.445% of all shares), a total value of $146.5 million in shares.
The next largest institutional holding, with 5.41 million shares, is of BLACKROCK INC.’s that is approximately 9.6998% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $73.08 million.
Also, the Mutual Funds coming in first place with the largest holdings of Stoke Therapeutics Inc (STOK) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.57 shares. This amounts to just over 2.91 percent of the company’s overall shares, with a $11.65 million market value. The same data shows that the other fund manager holds slightly less at 986.9, or about 1.82% of the stock, which is worth about $7.3 million.
